StockMirror — Stock Screener

MAXHEALTH Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: medium)

Earnings Summary

Max Healthcare reported strong Q2 FY27 results with 20% revenue growth, stable EBITDA margin at 26.8%, and PAT growth of 10% YoY. Occupancy remained steady at 77% despite 14% capacity addition. Management highlighted successful ramp-up of brownfield expansions and a robust pipeline of future projects. Regulatory headwinds in oncology and trade margin caps were discussed, with some impact but offset by CGHS price revisions. The company remains focused on both growth and margins, with expectations of accelerated growth in H2.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasizes capacity expansion for growth while maintaining stable margins through operating leverage and cost efficiencies.

About Max Healthcare Institute Limited

Max Healthcare Institute Limited (MAXHEALTH) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More